Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKNA Ikena Oncology	$1.37 +0.7%	$1.22	$0.97 ▼ $1.94	$66.11M	0.45	136,631 shs	26,434 shs
NGNE Neurogene	$18.30 -0.7%	$16.63	$6.88 ▼ $74.49	$261M	1.57	250,444 shs	203,614 shs
RNAC Cartesian Therapeutics	$10.00 +2.1%	$10.55	$8.46 ▼ $29.65	$259.54M	0.33	112,833 shs	49,305 shs
TNXP Tonix Pharmaceuticals	$34.32 -1.7%	$26.43	$6.76 ▼ $137.25	$252.50M	2.09	928,652 shs	479,527 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKNA Ikena Oncology	0.00%	0.00%	+21.24%	0.00%	-19.41%
NGNE Neurogene	0.00%	-10.29%	-1.35%	+28.78%	-39.64%
RNAC Cartesian Therapeutics	0.00%	-2.34%	-2.25%	-37.69%	-54.04%
TNXP Tonix Pharmaceuticals	0.00%	-0.64%	+14.78%	+49.02%	-71.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IKNA Ikena Oncology	3.6632 of 5 stars	3.3	5.0	3.8	1.7	1.3
NGNE Neurogene	3.7202 of 5 stars	4.4	3.0	1.9	2.5	1.3
RNAC Cartesian Therapeutics	1.5266 of 5 stars	3.4	0.0	1.5	3.3	0.0
TNXP Tonix Pharmaceuticals	3.04 of 5 stars	3.5	2.0	3.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKNA Ikena Oncology	2.50	Moderate Buy	$3.00	118.98% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	152.28% Upside
RNAC Cartesian Therapeutics	2.71	Moderate Buy	$43.00	330.00% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,604.55% Upside

Current Analyst Ratings Breakdown

Latest IKNA, TNXP, NGNE, and RNAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
5/8/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$41.00 ➝ $40.00
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00
4/9/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
4/9/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKNA Ikena Oncology	$9.16M	7.22	N/A	N/A	$2.61 per share	0.52
NGNE Neurogene	$930K	280.60	N/A	N/A	$20.89 per share	0.88
RNAC Cartesian Therapeutics	$38.91M	6.67	N/A	N/A	($0.27) per share	-37.04
TNXP Tonix Pharmaceuticals	$10.09M	25.03	N/A	N/A	$31.82 per share	1.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKNA Ikena Oncology	-$49.23M	-$0.86	N/A	N/A	N/A	N/A	-30.59%	-27.55%	8/14/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-7.01%	8/6/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	N/A	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)

Latest IKNA, TNXP, NGNE, and RNAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	IKNA Ikena Oncology	-$0.21	-$0.18	+$0.03	-$0.18	N/A	N/A
5/8/2025	Q1 2025	RNAC Cartesian Therapeutics	-$0.61	-$0.68	-$0.07	-$0.68	$0.69 million	$1.10 million
3/24/2025	Q4 2024	NGNE Neurogene	-$1.04	-$0.99	+$0.05	-$0.99	N/A	$0.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKNA Ikena Oncology	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKNA Ikena Oncology	N/A	13.31	13.31
NGNE Neurogene	N/A	21.03	21.03
RNAC Cartesian Therapeutics	N/A	12.34	12.34
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKNA Ikena Oncology	75.00%
NGNE Neurogene	52.37%
RNAC Cartesian Therapeutics	86.95%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
IKNA Ikena Oncology	5.94%
NGNE Neurogene	11.64%
RNAC Cartesian Therapeutics	60.30%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKNA Ikena Oncology	70	48.26 million	45.39 million	Not Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
RNAC Cartesian Therapeutics	64	25.95 million	10.30 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable

IKNA, TNXP, NGNE, and RNAC Headlines

Recent News About These Companies

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Here's What Happened

June 19 at 11:50 AM | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Time to Sell?

June 18 at 3:29 PM | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 9.9% Higher - Still a Buy?

June 16, 2025 | marketbeat.com

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

June 16, 2025 | seekingalpha.com

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...

June 16, 2025 | gurufocus.com

Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News

June 16, 2025 | gurufocus.com

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ...

June 16, 2025 | gurufocus.com

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

June 16, 2025 | globenewswire.com

Two Sigma Investments LP Makes New $66,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

June 14, 2025 | marketbeat.com

Millennium Management LLC Lowers Holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

June 14, 2025 | marketbeat.com

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim” Hunter, to Board of Directors

June 13, 2025 | manilatimes.net

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.8% - Time to Sell?

June 13, 2025 | marketbeat.com

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

June 13, 2025 | seekingalpha.com

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

June 13, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 10.1% - Here's What Happened

June 12, 2025 | marketbeat.com

Tonix Pharma Stock Plunges 20% Pre-market On Share Sale Announcement, But Retail’s Not Pessimistic

June 12, 2025 | msn.com

Tonix Pharmaceuticals stock falls after announcing $225 million share offerings

June 12, 2025 | investing.com

Tonix Pharmaceuticals (TNXP) Files To Raise $500 Million, Shares Tumble

June 12, 2025 | benzinga.com

Tonix Shares Fall After Entering Sales, Purchase Agreements

June 12, 2025 | marketwatch.com

Tonix Pharmaceuticals files $500M mixed securities shelf, shares down 15%

June 12, 2025 | seekingalpha.com

Tonix Pharma Signs Major Sales Agreements for Funding

June 11, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKNA, TNXP, NGNE, and RNAC Company Descriptions

Ikena Oncology NASDAQ:IKNA

$1.37 +0.01 (+0.74%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.35 -0.02 (-1.46%)

As of 06/18/2025 06:12 PM Eastern

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Neurogene NASDAQ:NGNE

$18.30 -0.12 (-0.65%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$18.30 0.00 (0.00%)

As of 06/18/2025 05:30 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Cartesian Therapeutics NASDAQ:RNAC

$10.00 +0.21 (+2.15%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$9.96 -0.04 (-0.40%)

As of 06/18/2025 04:04 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

Tonix Pharmaceuticals NASDAQ:TNXP

$34.32 -0.60 (-1.72%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$34.37 +0.05 (+0.15%)

As of 06/18/2025 07:55 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time